- Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
-
Ooi CJ, Hilmi IN, Kim HJ, Jalihal U, Wu DC, Demuth D, Lindner D, Adsul S
- KMID: 2512103
- Intest Res.
- 2021 Jan;19(1):71-82.
- doi: 10.5217/ir.2019.09159
Background/Aims: The efficacy and safety of vedolizumab in moderate to severely active ulcerative colitis (UC) have been demonstrated in the GEMINI 1 study (NCT00783718). This post-hoc exploratory analysis sought to... -
- CITED
-
- Close
- SHARE
-
- Close
- Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
-
Jun YK, Koh SJ, Myung DS, Park SH, Ooi CJ, Sood A, Im JP
- KMID: 2544758
- Intest Res.
- 2023 Jul;21(3):353-362.
- doi: 10.5217/ir.2023.00013
Background/Aims: Infectious complications are major concerns when treating patients with inflammatory bowel disease (IBD). This study evaluated clinical differences across countries/regions in the management of infectious diseases in patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
-
Park DI, Hisamatsu , Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK
- KMID: 2402643
- Intest Res.
- 2018 Jan;16(1):17-25.
- doi: 10.5217/ir.2018.16.1.17
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in... -
- CITED
-
- Close
- SHARE
-
- Close
- Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
-
Park DI, Hisamatsu , Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK
- KMID: 2402642
- Intest Res.
- 2018 Jan;16(1):4-16.
- doi: 10.5217/ir.2018.16.1.4
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in... -
- CITED
-
- Close
- SHARE
-
- Close
- Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
-
Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia G, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RA, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu , Yang SK, Ouyang Q, Geary R, De Silva J, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW, on behalf of the Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis
- KMID: 2454738
- Intest Res.
- 2019 Jul;17(3):285-310.
- doi: 10.5217/ir.2019.00026
The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD... -
- CITED
-
- Close
- SHARE
-
- Close
